[登录] [免费注册]
试剂仪器网
发布求购
位置：首页 > 产品库 > 4-P-PDOT
立即咨询
咨询类型：
     
*姓名：
*电话：
*单位：
Email：
*留言内容：
请详细说明您的需求。
*验证码：
 
4-P-PDOT
本产品不向个人销售，仅用作科学研究，不用于任何人体实验及非科研性质的动物实验。
4-P-PDOT图片
CAS NO:134865-74-0
包装与价格：
包装价格(元)
5mg电议
10mg电议
25mg电议
50mg电议

产品介绍
4-P-PDOT 是一种有效的、选择性的和亲和的褪黑激素受体 (MT2) 拮抗剂。
Cas No.134865-74-0
别名AH 024
化学名N-((2R,4R)-4-phenyl-1,2,3,4-tetrahydronaphthalen-2-yl)propionamide
Canonical SMILESO=C(CC)N[C@@H]1C[C@H](C2=CC=CC=C2)C3=CC=CC=C3C1
分子式C19H21NO
分子量279.38
溶解度15 mg/ml in DMSO, 30 mg/ml in DMF, 5 mg/ml in Ethanol
储存条件Store at -20℃
General tipsFor obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.
Shipping ConditionEvaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request
产品描述

4-P-PDOT is an antagonist of the melatonin 2 (MT2) receptor (pKi = 8.37) that displays 60-fold selectivity for MT2 over MT1.[1],[2] 4-P-PDOT is used in cells, explants, and animals to elucidate the role of MT2 in melatonin-mediated signaling.[3],[4]

Reference:
[1]. Browning, C., Beresford, I., Fraser, N., et al. Pharmacological characterization of human recombinant melatonin mt1 and MT2 receptors. Br. J. Pharmacol. 129(5), 877-886 (2000).
[2]. Dubocovich, M.L., Masana, M.I., Iacob, S., et al. Melatonin receptor antagonists that differentiate between the human Mel1a and Mel1b recombinant subtypes are used to assess the pharmacological profile of the rabbit retina ML1 presynaptic heteroreceptor. Naunyn-Schmiedeberg's Arch. Pharmacol. 355(3), 365-375 (1997).
[3]. Juszczak, M., Wolak, M., Bojanowska, E., et al. The role of melatonin membrane receptors in melatonin-dependent oxytocin secretion from the rat hypothalamo-neurohypophysial system - an in vitro and in vivo approach. Endokrynol. Pol. 67(5), 507-514 (2016).
[4]. Shin, E.-J., Chung, Y.-H., TLe, H.-L.T., et al. Melatonin attenuates memory impairment induced by Klotho gene deficiency via interactive signaling between MT2 receptor, ERK, and Nrf2-related antioxidant potential. Int. J. Neuropsychopharmacol. 18(6), (2015).